Invested in Simmunome, which uses AI to predict clinical trial outcomes via computational simulations.
Simmunome is a TechBio company providing a no-code, high-fidelity SaaS platform for AI-driven disease simulations, integrating protein networks, multi-omics data, and clinical evidence to guide drug development decisions
Simmunome is a TechBio company providing a no-code, high-fidelity SaaS platform for AI-driven disease simulations, integrating protein networks, multi-omics data, and clinical evidence to guide drug development decisions.